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MEDICATION MIGRATION
MIGRATION
MEDICATION
MEDICATION MIGRATION
By Clara Fenger, DVM, PhD, DACVIM, and Thomas Tobin, MRCVS, PhD, DABT

THE CHARLES TOWN NAPROXEN EXPERIENCE AND WHY IT MATTERS TO ALL
RACING JURISDICTIONS
Therapeutic medications are critical to the health of humans and animals
alike, and racehorses are no exception. To expect horses to perform at high
levels without the benefit of modern therapeutic medication is both unrealistic
and inhumane. All industry stakeholders agree that medication that impacts
performance or masks lameness at the time of competition needs to be
restricted, but turning back the clock to the time before we understood the
benefits of anti-inflammatory medication in counteracting the rigors of high32
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intensity performance is wrong for the industry as well as for the health and
welfare of the horse.
Collateral damage from the aggressive push of industry regulators to limit
the use of therapeutic medications has included the loss of any number of
medications previously in common use. Among those medications with valuable
applications in racehorses that have been unrealistically restricted
are isoxsuprine, methocarbamol and naproxen.

®iQoncept/Adobe Stock

GETTING TO KNOW
NAPROXEN
For many years, Equiproxen
ATTENDANT WITH [THE CHANGE IN CONTRACT LABORATORY] WAS A SUDDEN
was available as an FDA-approved,
safe and effective nonsteroidal antiSPORADIC PATTERN OF IDENTIFICATION OF LOW-CONCENTRATION NAPROXEN
inflammatory (NSAID) for horses.
POSITIVES [AT CHARLES TOWN]. … WHERE WERE THESE LOW-CONCENTRATION
Like humans, not all horses respond
similarly to all NSAIDs, and the
PLASMA NAPROXEN IDENTIFICATIONS COMING FROM?
availability of different FDA-approved
formulations allowed access of
appropriate anti-inflammatories
for horses in need of alternatives to
cannot impact a horse’s physiology in any way, these trace blood levels can be
phenylbutazone or flunixin. For that matter,
detected and may be called a positive in some jurisdictions. Common sense and
while it has not been available to the market in a number of years, Equiproxen
logic occasionally seem absent from the regulation of horse racing.
remains an FDA-approved medication for horses.
Despite Equiproxen’s lack of availability, veterinarians and horsemen
alike have continued to use naproxen, the FDA-approved human formulation,
for those horses in need of this alternative NSAID. In some jurisdictions, such
The likelihood of environmental contamination from naproxen causing
as Kentucky, warnings have been issued to avoid such use because traces of
a positive test has not been lost on the National Horsemen’s Benevolent and
naproxen can be detected for weeks after a relatively short course of treatment.
Protective Association, and the following alert was published in its book, World
Naproxen is usually recommended for back pain and relief of muscle
Rules for Equine Drug Testing and Therapeutic Medication Regulation: 2012
cramping in cases in which typical treatments like methocarbamol are
Policy of the National Horsemen’s Benevolent and Protective Association, by Dr.
ineffective alone.1 Additionally, naproxen is prescribed to horses with sore
Thomas Tobin, Dr. Kimberley Brewer and Kent Stirling:
feet to avoid injections of the coffin joints and navicular bursae, procedures
Naproxen is an oral medication. The dose is large, and naproxen seems to
that concern practitioners when required repeatedly.2 To provide the best
be chemically stable in the environment. Testing can be highly sensitive, and
possible care for the high-level athletes under their care, veterinarians
traces of naproxen have been detected for long periods after the last nominal
reach for naproxen in these specific instances in which other NSAIDs are not
administration, most likely associated with its environmental presence and
therapeutically effective.
resulting in inadvertent re-exposure. In April 2006, Kentucky recommended
“horsemen, veterinarians and owners to discontinue use of naproxen AT LEAST
120 hours before the race in which the horse is entered.”
Naproxen is a classic stall/environmental substance in the horse. It is a
high-dose oral NSAID used in both humans and horses. The dose to a horse is
Naproxen can be identified in horses for up to 47 days after the last
5-10 mg/kg or more administered orally once or twice a day, so the total daily
administration if the horse remains stabled in the same stall in which it was
dose can be as high as 10 grams/day. By modern analytical standards, this is
administered the medication (Wennerlund et al., 2000). More important, the
an amount that a chemist will trip over, making naproxen readily detectable
amount of naproxen identified in a horse that was never given naproxen but
in post-race plasma and urine samples. Additionally, naproxen is unusual in
stabled in the stall of a horse given naproxen can be indistinguishable from a
that it is a relatively small molecule; one gram of naproxen actually contains
horse actually given the drug. Although logic would dictate that the amount of
33 percent more naproxen molecules for the chemist to detect than one gram
medication that can be recycled in a horse from urine contamination
of phenylbutazone.

HORSEMEN’S ALERT ABOUT NAPROXEN

LOGIC OF IDENTIFYING NAPROXEN AT
LOW LEVELS

1
2

Nick Metinnis, DVM, personal communication
Mark Cheney, DVM, personal communication
WWW.HBPA.ORG
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INADVERTENT ENVIRONMENTAL EXPOSURE

The importance of inadvertent stall/environmental exposure as a source
of trace-level identifications was abruptly brought to the attention of the
racing world in Cambridge, England, in 2000, and naproxen was a charter
member of this first group of identified stall-contaminating medications. At
the International Conference of Racing Analysts and Veterinarians (ICRAV) that
year, no fewer than four papers were presented showing that the therapeutic
medications flunixin, naproxen, meclofenamic acid and isoxsuprine were all
significant stall contaminants, to the extent that a clean horse put into a
post-treatment stall immediately went “positive” just from exposure to the
post-treatment stall environment. In a paper from Hong Kong, it was shown
that cobwebs in a treatment stall contained the medication, immediately
explaining a number of unexpected isoxsuprine identifications. Since that time,
myriad papers in different journals have come to the same conclusion: Horses
can trigger readily identifiable positive tests in post-race samples from urine
contamination of their hay and bedding, even if the tested horse was never
administered the medication.
In fact, looking back with the wisdom of hindsight, our Canadian
colleagues had much earlier—around 1985 or so—seen the unusually
long time required for horses to “clear” naproxen after the nominal last
administration, showing that by 120 hours post-dosing plasma naproxen
concentrations had bottomed out at about 200 ng/ml or so and then
leveled out, not declining further. What was actually happening, of course, was
that the naproxen in the stall was re-contaminating the horses, and what our
Canadian colleagues were most likely measuring was evidence of the presence
of naproxen in the stalls of these horses, as pointed out by our Swedish
colleagues some 15 years later in their Cambridge 2000 ICRAV paper.

NAPROXEN ISSUES AT CHARLES TOWN

iStock.com/RASimon

Fast-forward another 15 years to Charles Town Races in West Virginia
in 2015, when Industrial Laboratories took over the state’s testing. When the
Association of Racing Commissioners International’s Controlled Therapeutic
Medication Schedule was introduced, the threshold for all substances not on

34
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the schedule went to zero tolerance, and the contract laboratory was changed
from Truesdail to Industrial Laboratories. Attendant with this change was
a sudden sporadic pattern of identification of low-concentration naproxen
positives. They were being reported at a rate of about one a month in plasma,
with concentrations ranging from 6 ng/ml to 160 ng/ml. The first question that
springs to mind is this: Where were these low-concentration plasma naproxen
identifications coming from?
Preliminary review of the data showed that one early plasma positive was
at 4,000 ng/ml, fully consistent with a recent full dose naproxen administration.
There were no further high-concentration naproxen identifications, suggesting
a lesson learned. All of the other naproxen identifications, however, were much
lower concentrations, the highest at 161 ng/ml and the balance below
100 ng/ml, with most below 50 ng/ml and one as low as 6.3 ng/ml, a very low
plasma concentration of naproxen.
An initial look at the low-concentration plasma identifications suggested
that they were associated with “ship-ins,” so the first theory was that the shipin stalls at Charles Town were contaminated with naproxen. Responding to this
possible explanation, the West Virginia Racing Commission reportedly sampled
the ship-in stalls and had the samples analyzed, but to our knowledge the
results of this testing have never been released.
We must also note that sampling a stall is one approach to this question
but that a more relevant, definitive and defendable approach is to simply put a
clean horse in the stall for a day or two and then take a blood and urine sample
from the horse. As suggested by the considerable scientific literature on the
subject, if the stall is actually significantly contaminated, the horse will test
positive for the medication in question, and a horse sniffing around the stall in
question for 24 to 48 hours is a much more definitive and defensible test than
simply “spot sampling” the stall with samples that may or may not pick up
what the horse will pick up and immediately transfer to his blood and urine.
Our next step was to review all of the individually claimed naproxen
identification information with the able assistance of Maria Catignani,
executive director of the Charles Town HBPA. When working on the data files,
we first looked at the jurisdictions from which the affected horse had shipped
in to Charles Town. It soon became apparent that a preponderance of these

horse had shipped in from the Mid-Atlantic states, which, it also soon became
apparent, had very different regulatory policies regarding naproxen compared to
West Virginia’s.
Based on discussions with veterinarians, chemists and other colleagues
and a review of testimony in those Mid-Atlantic cases, it was found that many if
not all of the Mid-Atlantic states have had a long-standing regulatory threshold
for naproxen of 1,000 ng/ml in plasma, a threshold that is apparently still in
place in these states.3
This finding immediately pointed to an additional possible source for these
low-concentration plasma identifications of naproxen, namely that they were
irrelevant trace-level residues of therapeutic administrations that “hung over”
in horses racing in the Mid-Atlantic when they shipped in to Charles Town.
None of these 161 ng/ml or less plasma residues identified in the Charles Town
positives would have raised an eyebrow in the Mid-Atlantic states. Additionally,
the range of values in these Charles Town ship-in identifications was
sufficiently low enough that their origins could reasonably be attributed to trace
residues of naproxen associated with inadvertent or unknowing stall exposure
to traces of the medication. In lay terms, horses in the Mid-Atlantic states are
racing with pharmacologically insignificant traces of naproxen in their plasmas.
The concentrations are well below where the Mid-Atlantic drug testing radar is
set for naproxen, but those concentrations have the potential to trigger a
trace-level identification positive in the now zero tolerance for naproxen at
Charles Town.
So, with regard to naproxen, it appears that Charles Town is a border
jurisdiction with horses from the Mid-Atlantic shipping in that are clean by
Mid-Atlantic levels but testing positive for traces of naproxen by Charles Town’s
new regulatory standards. Given this circumstance, the most practical approach
to this matter is to set a screening limit of detection for naproxen in Charles
Town that recognizes that horses from the Mid-Atlantic states will occasionally
tend to test above 6 ng/ml in plasma and to set an upper limit on this screening
limit of detection that accommodates the needs of these Charles Town
ship-in horses.
3

SETTING A SCREENING LIMIT FOR NAPROXEN

Taking this approach, we therefore reviewed the statistical spread of
the trace-level Charles Town plasma identifications and calculated the
concentrations at which “soft” and “hard” outliers of the trace-level naproxen
identification population occurred. This analysis placed the “hard” outlier
concentration at close to 250 ng/ml, which we selected as our recommended
screening limit of detection for the Charles Town authorities in this naproxen
matter.
We also reviewed how this proposed screening limit of detection compared
with the current list of regulatory thresholds for the RCI-controlled therapeutic
medication thresholds. Our analysis showed that this proposed screening limit
of detection for naproxen fell within the broad range of the RCI-controlled
therapeutic medication thresholds, confirming its suitability for use in
circumstances such as the Charles Town situation.
A detailed copy of this analysis, with extensive supporting documentation
and the proposed screening limit of detection solution, was presented to the
West Virginia Racing Commission as it reviewed these naproxen identifications.
The outcome was that a significant number of these identifications were
rescinded, although it is unclear at this time precisely what the new screening
limit of detection for naproxen in West Virginia is or will be.
That brings us to one final matter raised by these Charles Town events,
which is the status—or more correctly at this time the non-status—of
naproxen as an RCI-controlled therapeutic medication. Naproxen has a long
international history and an excellent safety record as a controlled therapeutic
medication as evidenced by the 1985 Canadian research and the 2000 Swedish
research, as well as its 30-year history as a controlled therapeutic medication
in the Mid-Atlantic states and its status as an FDA-approved medication in
horses. Given these circumstances, it may well be appropriate to recommend
to regulatory authorities outside of the Mid-Atlantic region that the decadeslong historical threshold for naproxen of 1 ug/ml be included in the RCI list of
controlled therapeutic medications based on its long-established worldwide
history of use as a safe and effective equine therapeutic medication.

George Maylin, DVM, personal communication

CONCLUSION

Rational thresholds for therapeutic medications need to be
considered in all jurisdictions to allow the reasonable treatment
of our precious athletes. The limitation of a practitioner’s
armamentarium to an arbitrary 28 or 30 medications, with limited
scientific basis for the thresholds, is at the very least unrealistic
and at worst endangers the health and welfare of the horse. The
West Virginia Racing Commission took the high road in the case of
naproxen, choosing a reasonable threshold, and other jurisdictions
should take notice. In a recent case in Kentucky, both the absolute
insurer rule and the arbitrary threshold for methocarbamol were
successfully challenged. Racing commissions across the country
need to pay attention and follow the lead of West Virginia. Rational
regulation of therapeutic medications avoids costly legal battles and
allows our regulators to get back to the business of promoting horse
racing and fighting the real threats to the integrity of our sport.
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